S
INO icon

SignatureFD’s Inovio Pharmaceuticals INO Stock Holding History

SignatureFD’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-18
Closed -$174 – 3298
2023
Q1 		$174 Sell
18
-117
-87% -$2K ﹤0.01% 3198
2022
Q4 		$2.52K Buy
135
+95
+238% +$2.15K ﹤0.01% 2726
2022
Q3 		$1K Buy
+40
New +$1.02K ﹤0.01% 2976
2022
Q2 		– Sell
-127
Closed -$5K – 3224
2022
Q1 		$5K Buy
127
+89
+234% +$4.01K ﹤0.01% 2480
2021
Q4 		$2K Sell
38
-160
-81% -$12.8K ﹤0.01% 2734
2021
Q3 		$17K Sell
198
-39
-16% -$3.91K ﹤0.01% 1830
2021
Q2 		$26K Buy
237
+222
+1,480% +$21.3K ﹤0.01% 1614
2021
Q1 		$2K Buy
15
+9
+150% +$1.18K ﹤0.01% 2484
2020
Q4 		$1K Buy
+6
New +$799 ﹤0.01% 2440
2014
Q3 		– Sell
-208
Closed -$27K – 807
2014
Q2 		$27K Buy
+208
New +$24.5K 0.01% 322

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

SignatureFD's INO Position: Q2 2023 in Review

SignatureFD sold out of Inovio Pharmaceuticals (INO) in Q2 2023, closing a stake of 18 shares — an estimated $174 sold.

SignatureFD first reported a position in INO in Q2 2014 and held it in 10 quarters. The position peaked at $27K in Q2 2014. 133 funds tracked by Wall St. Rank hold INO as of Q2 2023.

  • SignatureFD reported no remaining Inovio Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • SignatureFD sold 18 Inovio Pharmaceuticals shares in Q2 2023, an estimated $174.
  • SignatureFD first reported a position in Inovio Pharmaceuticals in Q2 2014 and held it in 10 quarters.
  • SignatureFD's Inovio Pharmaceuticals position peaked at $27K in Q2 2014.
  • 133 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2023.

Based on SignatureFD's 13F filing for Q2 2023, filed 1 Aug 2023.